For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 ...

Issuers still hold the key role in fighting fraud without compromising customer experience. A proactive issuer strategy ...

Check the time stamp on this data. Updated AI-Generated Signals for Centerpoint Energy Inc (holding Co) (CNP) available here: ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...

CenterPoint Energy Inc. closed $3.40 short of its 52-week high ($31.57), which the company achieved on June 21st.

(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...

In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...

“Thank you so much. Honestly, the things that we run out of and that we’re low on the most are mattresses, bed frames, linens ...

Copenhagen-based Ascendis designed the trial to compare its once-weekly prodrug of C-type natriuretic peptide (CNP) to ...

American depositary receipts of Ascendis Pharma A/S rose 15% on topline data from a trial of TransCon CNP, a potential treatment for children with achondroplasia. ADRs were trading around $137. ADRs ...

First Day of Fall Arrives across the Gulf Coast Region, but Hurricane Season Remains in Full Force <li /> CenterPoint <a ...